Diiodohydroxyquinoline

Diiodohydroxyquinoline (Iodoquinol, 5,7-Diiodo-8-hydroxyquinoline, 5,7-Diiodo-8-quinolinol) has an orally active and satisfactory antiparasitic properties. Diiodohydroxyquinoline exhibits mutagenic potential in mice and potent anti-SARS-CoV-2 activity with an EC50 value of 1.38 μM in VeroE6 cells. Diiodohydroxyquinoline's antimutagen is ascorbic acid. Diiodohydroxyquinoline is promising for research in inflammationin, testinal amebiasis, amebic liver abscess and chronic nonspecific diarrheas[1][2][3][4][5].

Product Specifications

CAS Number

[83-73-8]

Product Name Alternative

Iodoquinol; 5,7-Diiodo-8-hydroxyquinoline; 5,7-Diiodo-8-quinolinol

UNSPSC

12352005

Hazard Statement

H302, H318

Target

Parasite; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Diiodohydroxyquinoline.html

Purity

99.0

Solubility

DMSO : 20.83 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL

Smiles

OC1=C2N=CC=CC2=C(I)C=C1I

Molecular Formula

C9H5I2NO

Molecular Weight

396.95

Precautions

H302, H318

References & Citations

[1]Martínez-Castillo M, et al. Flavonoids as a Natural Treatment Against Entamoeba histolytica. Front Cell Infect Microbiol. 2018 Jun 22;8:209.|[2]Ghaskadbi S, et al. In vivo antimutagenic effect of ascorbic acid against mutagenicity of the common antiamebic drug diiodohydroxyquinoline[J]. Mutat Res. 1989 Mar;222 (3) :219-22. |[3]Yuan S, et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system[J]. Pharmacol Res. 2020 Sep;159:104960.|[4]Chandramohan H. Asrani, et al. Efficacy and safety of metronidazole versus a combination of metronidazole and diiodohydroxyquinoline for the treatment of patients with intestinal amebiasis: a primary care physician research group study[J]. 1995 July, 56 (7) : 678-683.|[5]Cohlan SQ. Chronic nonspecific diarrhea in infants and children treated with diiodohydroxyquinoline. Pediatrics. 1956 Sep;18 (3) :424-32.